Cav-1 expression in prostate tumors has been shown to be an independent risk factor for the occurrence of CRPC, and is associated with a shorter recurrence-free survival time in these patients.(26) Simvastatin was shown to augment the anticancer effects of androgen receptors antagonists by downregulating the expression of Cav-1. This evidence concerns the gene AR and prostate neoplasm.